OR WAIT 15 SECS
Ashland Specialty Ingredients opened a drug development and bioavailability enhancement facility in Wilmington, Delaware.
Ashland Specialty Ingredients opened a facility to focus on drug development, bioavailability enhancement, and contract development for solid dispersions and oral solid-dosage forms. The facility is located in Wilmington, Delaware and has capabilities including spray drying, hot-melt extrusion, and potent-compound processing suites.
"Research and development (R&D) dedicated to drug development and bioavailability enhancement is essential to the future success of the pharmaceutical manufacturing industry. Emerging manufacturing processes, such as continuous manufacturing by spray drying or hot-melt extrusion, is one component of this equation. Excipients science is another,” said Jim Mish, group vice president, Consumer Specialties, Ashland Specialty Ingredients in a press release. “At our new center of excellence, we will be combining our expertise in process technology along with our knowledge in materials science to further support the quality, safety and efficiency of oral solid-dosage forms.”
Ashland Specialty Ingredients is focused on solutions in the pharmaceutical and nutraceutical industries. It now has 10 centers around the world for research, development, and technical support.